ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0036498;IRE1-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;55.46397693329154;5.825829909099042;0.0018563293936187412;0.6210535250702663;[ERN1, SYVN1]
GO:1901222;regulation of NIK/NF-kappaB signaling;7.0;0.8436909121759173;0.7727648213451592;9.34084218004034;45.070113835906206;5.223196736079928;0.001508456149618737;0.6180338892438164;[PRDX1, ZFP91]
GO:0061337;cardiac conduction;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;31.820364139744015;5.9928839937622085;0.0010649989512887435;0.6573957313958061;[KCNK6]
GO:0072583;clathrin-dependent endocytosis;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;30.046907922432062;6.558197802812269;0.0010056429677022863;0.6863059058804069;[CLTA]
GO:0051882;mitochondrial depolarization;5.0;1.0;0.7902410118609202;9.628524252492122;25.75696197398942;8.67846133901236;8.620623375086068E-4;0.7340579283277371;[ATPIF1]
GO:1905818;regulation of chromosome separation;6.0;0.6417349323569144;0.6439877787686017;8.529911963824013;31.575448191934637;5.682729065458369;0.0010568018349256063;0.6137353412716126;[CSNK2A1, TPR, ANAPC5, ANAPC11]
GO:0071498;cellular response to fluid shear stress;4.0;0.7980440201809971;0.6490220100904985;9.271849308553389;39.92524609926753;6.8867018697843045;0.0013362620565537933;0.6021862538851576;[HDAC3]
GO:0050434;positive regulation of viral transcription;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;62.40780878563472;6.7325511899570465;0.0020887331966737226;0.6952223462072524;[CDK9, EP300, CHD1]
GO:0030819;positive regulation of cAMP biosynthetic process;11.0;0.8653626801206646;0.8651102923899945;9.57973408832269;5453.910874973866;6.599019797332524;0.18253748878425521;0.7699031316510512;[CALM1]
GO:0048008;platelet-derived growth factor receptor signaling pathway;8.0;0.7763722522362496;0.7631861261181248;9.186691500213083;31.002284443533863;6.280566066213989;0.0010376185600805164;0.6961884407023742;[SGPL1]
GO:0060236;regulation of mitotic spindle organization;9.0;0.7980440201809971;0.7952626352707877;9.360260265897443;71.51327617590798;6.193554689224359;0.0023934849958375417;0.7129793000169707;[STAG2, TPR, NUP62]
GO:0005513;detection of calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;27.95353479882516;7.212124270218933;9.355796531686605E-4;0.6919486831672181;[CALM1]
GO:0006605;protein targeting;9.0;0.7192862368539868;0.7558837436072825;9.182237149863703;93.4429707305496;4.015022244900292;0.0031274521371376313;0.6015690495021188;[PEX16, AP3M1, TRAM1, PEX19, PAN3, SSR2, VPS41, HSD17B4, TRAK1]
GO:0051770;positive regulation of nitric-oxide synthase biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.069023426578259;0.0049295844405465;0.7124295520356204;[FNTB]
GO:0006606;protein import into nucleus;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;277.5355368998559;5.288437257948329;0.009288864654271135;0.6666915524892495;[NUP62, NUP153, TNPO2, KPNB1]
GO:0071243;cellular response to arsenic-containing substance;4.0;0.8653626801206646;0.6826813400603323;9.377209824211215;38.7152913866576;7.138016298065211;0.0012957659612112835;0.6150384854347593;[ZFAND2A]
GO:0035269;protein O-linked mannosylation;9.0;1.0;0.896240625180289;9.628524252492122;364.0992215367897;7.069023426578259;0.012186073276810977;0.757750811958709;[DPM3]
GO:0048490;anterograde synaptic vesicle transport;10.0;1.0;0.9152410118609203;9.628524252492122;439.1991285038257;7.004484905440688;0.014699599577469427;0.7734506956670166;[AP3M1]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[WDR48, NDUFS6, TMED2]
GO:0036111;very long-chain fatty-acyl-CoA metabolic process;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;93.60244388508701;9.777073627680469;0.0031327895601034775;0.8509193652572005;[HSD17B4]
GO:0043922;negative regulation by host of viral transcription;11.0;1.0;0.9324289523296623;9.628524252492122;272.3838172918008;7.292166977892469;0.009116441235236167;0.8053507106995271;[HDAC1]
GO:0036112;medium-chain fatty-acyl-CoA metabolic process;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;93.60244388508701;8.390779266560578;0.0031327895601034775;0.7800242071602487;[HSD17B4]
GO:0000398;mRNA splicing, via spliceosome;11.0;0.8259837884571596;0.845420846558242;9.4949928598676;356.66873027722005;4.19357731889877;0.011937381421361158;0.6468886914394342;[SF3B5, AQR, SF3B2, GPKOW, CPSF2, DDX42, DDX41, USP39, SRRM1, EFTUD2, PABPN1, PCF11, U2AF2, POLR2B, SNRPG, SNRPB2, POLR2G, SLU7, SMNDC1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[CALM1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[SETX, KARS, PABPN1, PTPRA, CALM1]
GO:0006814;sodium ion transport;7.0;0.811012628672052;0.7564256795932265;9.310070521373587;34.16983994150393;4.629579150867016;0.001143633791982704;0.5876762583299873;[SLC9A6, COMMD3]
GO:0051300;spindle pole body organization;4.0;0.8436909121759173;0.6718454560879586;9.271849308553389;37.692070457630365;7.8311634786251565;0.0012615196775557923;0.6504860644832351;[CALM1]
GO:0071157;negative regulation of cell cycle arrest;7.0;1.0;0.8509193652572005;9.628524252492122;127.41368125290029;6.641579411751319;0.004264421246666119;0.6905700452391912;[CDK9]
GO:0048268;clathrin coat assembly;6.0;0.8436909121759173;0.7449657686781032;9.310070521373587;44.51706700895919;6.781341354126479;0.0014899461700306506;0.6699184248047958;[CLTA]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[FNTB]
GO:0048025;negative regulation of mRNA splicing, via spliceosome;10.0;0.9326813400603323;0.8815816818910864;9.593432932680852;1181.5966005326304;6.781341354126479;0.03954697485192635;0.7620391240755716;[U2AF2]
GO:0098957;anterograde axonal transport of mitochondrion;10.0;1.0;0.9152410118609203;9.628524252492122;301.35626879386905;8.67846133901236;0.010086123113496874;0.8590579283277371;[TRAK1]
GO:0036109;alpha-linolenic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;214.3732045654151;7.212124270218933;0.0071748782334459795;0.7650689957573628;[ELOVL5, HSD17B4, FADS1]
GO:2000270;negative regulation of fibroblast apoptotic process;8.0;1.0;0.875;9.628524252492122;103.9210822679579;7.9853141584524145;0.0034781451006065307;0.7833693374183408;[CFDP1]
GO:0060252;positive regulation of glial cell proliferation;9.0;0.8933024483968273;0.8428918493787028;9.587702257971866;465.4406966640378;7.292166977892469;0.015577881247913653;0.769162383550154;[PPP1CC]
GO:1904766;negative regulation of macroautophagy by TORC1 signaling;9.0;1.0;0.896240625180289;9.628524252492122;295.54083717263194;9.777073627680469;0.009891485850682736;0.896240625180289;[CLEC16A]
GO:0071391;cellular response to estrogen stimulus;4.0;1.0;0.75;9.628524252492122;34.48118488206192;7.069023426578259;0.001154054226950925;0.6115101867784198;[TRIM24]
GO:1903438;positive regulation of mitotic cytokinetic process;9.0;0.7436939687323844;0.7680876095464813;9.223059144383958;347.7403829701856;9.083926447120524;0.011638557671985614;0.8607930461318132;[NUP62]
GO:0005977;glycogen metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.523163736834295;182.57737249811964;5.885253329569843;0.006110700348544658;0.6518914942236709;[PPP1CB, PPP1CC]
GO:0006707;cholesterol catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;394.5590965539014;7.292166977892469;0.013205537881525935;0.7238411236270654;[SNX17]
GO:0070054;mRNA splicing, via endonucleolytic cleavage and ligation;10.0;1.0;0.9152410118609203;9.628524252492122;355.57011798855257;9.777073627680469;0.011900611856746327;0.9152410118609203;[ERN1]
GO:0000291;nuclear-transcribed mRNA catabolic process, exonucleolytic;10.0;0.7980440201809971;0.8142630219514189;9.5544162803384;717.2549128915896;6.221725566191056;0.0240058764469685;0.7334203466557586;[CNOT6, POLR2G, CNOT8, DCP2]
GO:0070059;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.12593595584649;6.343086423195323;0.002815619368015229;0.6753050999230941;[ERN1]
GO:0036297;interstrand cross-link repair;8.0;0.8933024483968273;0.8216512241984136;9.541512875502493;183.0506323445446;5.905872616772578;0.006126539929698291;0.6770266002729131;[DCLRE1C]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[TRAM1, AHCYL1, RABGAP1, CLTA, HSD17B4, TRAK1, RAB21, AP3M1, NUP62, TMED2, EVI5L, TNPO2, TBC1D22A, PEX16, VPS18, TMED9, PEX19, SSR2, COG3, SYVN1, NUP153, ARCN1, PAN3, SNX17, VPS41, RAB18, SEC24C, SLU7, KPNB1]
GO:0006402;mRNA catabolic process;8.0;0.6696747006330769;0.7098373503165385;9.232108979903876;713.3837118806829;4.434739375715658;0.02387631083298817;0.6017927779105702;[UPF2, ERN1, CNOT6, PAN3, CNOT1, CNOT10, POLR2G, CNOT8, SMG5, DCP2]
GO:0003376;sphingosine-1-phosphate signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;50.14720301582843;7.292166977892469;0.001678381755387122;0.6960420709600095;[SPHK2]
GO:0006401;RNA catabolic process;7.0;0.5945822691631375;0.6482104998387692;8.775746926340293;532.6118641417924;4.304802954008995;0.01782603977326812;0.5710671885190304;[UPF2, ERN1, CNOT6, PAN3, CNOT1, CNOT10, POLR2G, CNOT8, SMG5, DCP2, SND1]
GO:0006517;protein deglycosylation;7.0;0.7671156992804218;0.7344772148974115;9.326243380619188;247.8243933626011;6.311337724880743;0.008294459418372403;0.6736814700148209;[MAN2B2, SYVN1]
GO:0032922;circadian regulation of gene expression;6.0;1.0;0.8231203125901445;9.628524252492122;31.18462308171688;5.769740442447999;0.0010437212702063816;0.618185107137305;[PPP1CB, PPP1CC, HDAC1]
GO:0031954;positive regulation of protein autophosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;6.481236761676141;0.026061291479152104;0.7466917612613706;[CALM1]
GO:1903839;positive regulation of mRNA 3'-UTR binding;7.0;1.0;0.8509193652572005;9.628524252492122;58.05927360831535;9.777073627680469;0.0019431916377164215;0.8509193652572005;[CDK9]
GO:0032802;low-density lipoprotein particle receptor catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;464.4154505485325;7.474488534686424;0.01554356718308929;0.7331650565203278;[CLTA]
GO:0071333;cellular response to glucose stimulus;8.0;1.0;0.875;9.628524252492122;272.3004295980195;5.69953618377475;0.009113650324169357;0.6664745454937787;[ERN1]
GO:0070126;mitochondrial translational termination;7.0;1.0;0.8509193652572005;9.628524252492122;40.68669918132259;5.277263957350204;0.0013617472059468932;0.6207988894539612;[MRPS22, MRPS18A, MRPL17]
GO:0050999;regulation of nitric-oxide synthase activity;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;24.724602712185703;6.039404009397101;8.275102020790521E-4;0.6319757144917204;[CALM1]
GO:0070125;mitochondrial translational elongation;7.0;1.0;0.8509193652572005;9.628524252492122;106.95016378538953;5.299736813202263;0.0035795257329985885;0.6219481523473303;[MRPS22, MRPS18A, MRPL17]
GO:2001243;negative regulation of intrinsic apoptotic signaling pathway;9.0;0.7436939687323844;0.7680876095464813;9.413412872875176;597.3701724921605;5.233778845410465;0.0199934420750612;0.663896318730187;[SYVN1, VDAC2]
GO:1901796;regulation of signal transduction by p53 class mediator;7.0;0.7192862368539868;0.710562483684194;9.117698628726131;45.070113835906206;4.948759890378168;0.001508456149618737;0.6039991761920099;[TBP, CSNK2A1, TRIM24, EP300, TAF7, SENP2, RFFL]
GO:0060316;positive regulation of ryanodine-sensitive calcium-release channel activity;14.0;1.0;0.9759193652572005;9.628524252492122;2786.515379930216;7.697632086000634;0.09326216206523613;0.8695766281117727;[CALM1]
GO:0048205;COPI coating of Golgi vesicle;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;22.707504301080803;7.9853141584524145;7.599997335300838E-4;0.7592887026755414;[TMED9, TMED2]
GO:1900103;positive regulation of endoplasmic reticulum unfolded protein response;8.0;0.8653626801206646;0.8076813400603323;9.481920778300246;307.4132605156266;7.212124270218933;0.010288845175485454;0.7438283705770736;[ERN1]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[SYNJ1, SNX17, CLTA, RABEPK]
GO:0006412;translation;7.0;0.8653626801206646;0.7836007053175329;9.510741216835738;402.5585345733233;4.39257856489138;0.01347327187300917;0.5755560373415389;[RPL36AL, MRPS18A]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[TRAPPC2, TRAPPC3, TRAPPC6B, TMED2, SEC24C]
GO:0060315;negative regulation of ryanodine-sensitive calcium-release channel activity;11.0;1.0;0.9324289523296623;9.628524252492122;2557.621706734507;7.379178354882098;0.08560129681430756;0.8098004765652196;[CALM1]
GO:0006406;mRNA export from nucleus;9.0;0.8933024483968273;0.8428918493787028;9.523163736834295;121.36021434248079;5.132682728539097;0.004061817156940898;0.658726258611935;[UPF2, ALKBH5, PABPN1, U2AF2, TPR, CPSF2, NUP62, NUP153, SLU7, SMG5, SRRM1]
GO:0007614;short-term memory;7.0;1.0;0.8509193652572005;9.628524252492122;22.22653164046661;7.57984905034425;7.439020114266185E-4;0.738553198190834;[COMT]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[TRAPPC2, DCTN5, TRAPPC3, TMED9, DCTN4, COG3, DYNLL2, ARCN1, SPAST, TRAPPC6B, GOLGB1, TMED2, SEC24C]
GO:0009913;epidermal cell differentiation;5.0;0.7436939687323844;0.6620879962271125;8.712233520617966;24.20171999872632;5.277263957350204;8.100097882234571E-4;0.560120536057681;[HDAC1]
GO:0030970;retrograde protein transport, ER to cytosol;10.0;1.0;0.9152410118609203;9.628524252492122;126.6472701115644;7.004484905440688;0.004238770155490853;0.7734506956670166;[SYVN1]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[UBE2I, RNF38, SYVN1, ZFP91, FBXL15, ANAPC11, VCPIP1, HERC1, KCTD10, TRIM24, FBXL3, ANAPC5, RFFL, C18orf25]
GO:0036158;outer dynein arm assembly;7.0;1.0;0.8509193652572005;9.628524252492122;45.210214189519135;6.7325511899570465;0.0015131451823720294;0.6952223462072524;[TMEM141]
GO:0006622;protein targeting to lysosome;11.0;0.9326813400603323;0.8987696223598284;9.592156608321247;250.3799473132135;6.781341354126479;0.008379991509250163;0.7792270645443136;[AP3M1]
GO:1904837;beta-catenin-TCF complex assembly;5.0;1.0;0.7902410118609202;9.628524252492122;40.42272244673708;6.409777797693995;0.0013529121422039536;0.618037346520142;[TLE4, HDAC1, EP300]
GO:0006613;cotranslational protein targeting to membrane;11.0;0.9326813400603323;0.8987696223598284;9.584072489921288;151.34345246524913;5.223196736079928;0.005065329153747539;0.6995434763162781;[TRAM1, SSR2]
GO:1904707;positive regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.75549718811011;6.444869117505266;0.0027028138156570515;0.6805102716434839;[ERN1]
GO:0071470;cellular response to osmotic stress;5.0;0.6997970393407541;0.6401395315312973;8.986670366319727;76.3083833169515;6.409777797693995;0.002553972916532016;0.618037346520142;[SERPINB6]
GO:0050772;positive regulation of axonogenesis;10.0;0.7436939687323844;0.7870879962271125;9.36383169826504;884.0118179988558;5.395046993006588;0.02958707998943757;0.6911439659786198;[TRAK1, PAFAH1B1]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[FBXL15, CLASP1, PAFAH1B1]
GO:0047496;vesicle transport along microtubule;8.0;0.7866048967936545;0.7683024483968273;9.36615998802463;173.0068769504478;6.039404009397101;0.005790384475450878;0.6838554019015759;[AP3M1, TRAK1, PAFAH1B1]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[POLE4]
GO:0016310;phosphorylation;5.0;0.5310727365277519;0.5557773801247963;6.876988939450173;24.405590426795786;2.7321685105510984;8.168331479794688E-4;0.42996423654933263;[PDXK, ATP5I, COX5B, ATP5O, ATP5L, ZMYM2, PABPN1, TRIM24, STK38L, CYC1, TPI1, CSNK2A1, SPHK2, CLK4, SETX, CLK1, ERN1, CDK9, GNPTG, SNRK, PAN3, KARS, PTPRA, FASTKD5, CALM1]
GO:0016311;dephosphorylation;5.0;0.6835726970475526;0.6320273603846966;8.32924126836186;24.405590426795786;4.076630054289783;8.168331479794688E-4;0.4987200624199847;[PPP1CB, PTP4A1, PPP1CC, DUSP23, G6PC3, SYNJ1, PTPRA, DUSP28, PPM1G]
GO:1900364;negative regulation of mRNA polyadenylation;11.0;1.0;0.9324289523296623;9.628524252492122;727.4995684895773;7.697632086000634;0.024348755850241696;0.8260862151842345;[CDK9]
GO:0060213;positive regulation of nuclear-transcribed mRNA poly(A) tail shortening;11.0;1.0;0.9324289523296623;9.628524252492122;968.1421379136862;7.379178354882098;0.03240284608461468;0.8098004765652196;[CNOT1, POLR2G]
GO:0006631;fatty acid metabolic process;7.0;0.5408746917014966;0.6213567111079488;7.849668188099975;91.0232021896581;4.037280715501235;0.0030464646617242943;0.5573860888006872;[SGPL1, ELOVL5, NDUFS6, HSD17B4, FADS1]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[TLE4, HDAC1, DVL3]
GO:0006506;GPI anchor biosynthetic process;9.0;0.7980440201809971;0.7952626352707877;9.474373572664863;1288.6226301771758;6.558197802812269;0.04312903974695605;0.7316271658034954;[DPM3]
GO:0070493;thrombin-activated receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;7.57984905034425;9.028936615729279E-4;0.710754145523778;[IQGAP2]
GO:0002027;regulation of heart rate;7.0;0.7043150770688792;0.7030769037916401;8.712233520617966;26.867502833526505;5.233778845410465;8.992311406554274E-4;0.6185750588070984;[CALM1]
GO:0006625;protein targeting to peroxisome;10.0;0.8933024483968273;0.861892236059334;9.56183287799345;237.37488197280172;5.572381008289503;0.007944723676105511;0.7002128357670632;[PEX16, PEX19, HSD17B4]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[PABPN1]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[BECN1, UBE2I, WDR48, PDCD6IP, RNF38, SYVN1, FBXL15, SENP2, USP39, PARL, ANAPC11, YY1, SENP6, PSMD8, KBTBD4, VCPIP1, XPNPEP1, KCTD10, PSMB1, CASP2, FBXL3, ANAPC5, RFFL, C18orf25]
GO:0071345;cellular response to cytokine stimulus;5.0;0.6729672293956388;0.6267246265587396;8.214830917184116;61.59823360834823;3.805811787890007;0.0020616374440603005;0.48487040368196277;[YY1, TLE4, CDK9, DOCK8, TPR, MTF2, CIB1, DDX41]
GO:0050668;positive regulation of homocysteine metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;707.5305157476903;9.777073627680469;0.02368040962595143;0.896240625180289;[COMT]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[TRAM1, AHCYL1, SYS1, RABGAP1, CLTA, HSD17B4, TRAK1, RAB21, EIF4ENIF1, AP3M1, NUP62, TMED2, EVI5L, TNPO2, SNAP29, TBC1D22A, ATP6V1F, PEX16, VPS18, TMED9, PDCD6IP, PEX19, SSR2, VPS33B, COG3, SYVN1, NUP153, SENP2, ARCN1, PAN3, SNX17, VPS41, RAB18, SEC24C, SLU7, KPNB1, PAFAH1B1, EXOC1]
GO:0002087;regulation of respiratory gaseous exchange by neurological system process;6.0;1.0;0.8231203125901445;9.628524252492122;40.361908422019745;7.212124270218933;0.0013508767515257331;0.6919486831672181;[PBX3]
GO:0042776;mitochondrial ATP synthesis coupled proton transport;13.0;1.0;0.9625549647676366;9.628524252492122;10144.915177257948;6.943860283624253;0.3395411811519228;0.8176643025947071;[ATP5I, CYC1, COX5B, ATP5O, ATP5L]
GO:0032968;positive regulation of transcription elongation from RNA polymerase II promoter;12.0;1.0;0.9481203125901445;9.628524252492122;3433.0515732151193;6.8867018697843045;0.11490114660968445;0.8003065664753022;[CDK9]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[MTPN, CSNK2A1, CIB1, PAFAH1B1]
GO:0051123;RNA polymerase II transcriptional preinitiation complex assembly;8.0;1.0;0.875;9.628524252492122;67.28910983117808;6.7325511899570465;0.002252105949782328;0.719302980950052;[TBP, TAF7, MED6]
GO:1990126;retrograde transport, endosome to plasma membrane;6.0;0.8653626801206646;0.7558016526504768;9.533214072687796;64.06213751966278;6.7325511899570465;0.0021441020906024424;0.6674232935401965;[SNX17]
GO:0010815;bradykinin catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;198.73492378151718;8.16763571524637;0.00665147904914789;0.7686126355688037;[XPNPEP1]
GO:0016256;N-glycan processing to lysosome;7.0;1.0;0.8509193652572005;9.628524252492122;98.05593499944818;9.083926447120524;0.0032818438998193566;0.8154717862087246;[GNPTG]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[DCTN5, DCTN4, CLTA, SEC24C, DYNLL2]
GO:2001168;positive regulation of histone H2B ubiquitination;12.0;0.9326813400603323;0.9144609826203107;9.60254876608886;1491.568393434329;8.390779266560578;0.04992145180384398;0.8772251544931927;[CDK9]
GO:0090502;RNA phosphodiester bond hydrolysis, endonucleolytic;8.0;0.6799073451904818;0.7149536725952409;8.878218658092228;231.13671471601307;5.395046993006588;0.007735937832006836;0.6509029541176994;[ERN1, RPP21]
GO:0042789;mRNA transcription by RNA polymerase II;11.0;1.0;0.9324289523296623;9.628524252492122;1288.3918881325048;6.832634648514029;0.043121317018375266;0.781850206004675;[TFCP2]
GO:0042306;regulation of protein import into nucleus;8.0;0.8259837884571596;0.7879918942285797;9.510741216835738;189.4811146876517;5.618190544320798;0.006341762386663705;0.6623145257091445;[HDAC3, TPR, NUP62]
GO:0045814;negative regulation of gene expression, epigenetic;7.0;0.7671156992804218;0.7344772148974115;9.081980546124052;80.1036275103501;5.2552850506314295;0.0026809963241870454;0.6196748871422394;[HDAC1, MTF2]
GO:0042307;positive regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;778.7460608588023;6.063501560976162;0.02606392983099081;0.706328376990269;[HDAC3, TPR]
GO:0045815;positive regulation of gene expression, epigenetic;7.0;0.7763722522362496;0.7391054913753253;9.081980546124052;79.85422672196849;5.8650506222523235;0.0026726491042460506;0.6508583268319309;[TBP, EP300]
GO:0042420;dopamine catabolic process;8.0;1.0;0.875;9.628524252492122;561.0959123607433;7.697632086000634;0.018779375233177315;0.7686572628545723;[COMT]
GO:0006699;bile acid biosynthetic process;8.0;1.0;0.875;9.628524252492122;493.34951140512965;6.481236761676141;0.01651196416099542;0.7064507494004503;[HSD17B4]
GO:0009966;regulation of signal transduction;5.0;0.3290196849396939;0.45475085433076723;5.351858133476067;37.58855813399747;1.7469895334129066;0.0012580552132388425;0.37958213784297784;[ANKRD17, BECN1, HDAC3, HDAC1, CLEC16A, CIB1, GLG1, RDH11, PRDX1, NUP62, TRIM24, DVL3, CASP2, EP300, RFFL, TLE4, UBE2I, TBP, CSNK2A1, ATPIF1, SYVN1, ZFP91, FBXL15, SENP2, ERN1, KARS, SLC9A6, ALS2, CNOT1, TAF7, VDAC2, PKP4, SERINC3, CALM1, PAFAH1B1]
GO:0042304;regulation of fatty acid biosynthetic process;7.0;0.6954798709641801;0.6986593007392905;9.0094850440859;138.57858976749046;6.113511981550823;0.004638100686884144;0.663564652301091;[ELOVL5, SCAP]
GO:0016241;regulation of macroautophagy;7.0;0.6729672293956388;0.6874029799550199;8.606873004960141;45.30384692040349;4.7081694254602375;0.0015162789856107417;0.5916953686275062;[ERN1, BECN1, CALCOCO2, CLEC16A, EXOC1]
GO:0018406;protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan;10.0;1.0;0.9152410118609203;9.628524252492122;518.4627997500709;7.8311634786251565;0.01735248332140844;0.8157270763441555;[DPM3]
GO:0045948;positive regulation of translational initiation;9.0;0.7586651285174919;0.775573189439035;9.39368466141472;1253.3709905068713;6.409777797693995;0.04194919909160693;0.7240369598395108;[POLR2G]
GO:0043647;inositol phosphate metabolic process;6.0;0.7436939687323844;0.6949672969563367;9.280217558223907;87.6170970844922;5.769740442447999;0.002932465389149971;0.618185107137305;[SYNJ1, CALM1, NUDT3]
GO:0040014;regulation of multicellular organism growth;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;36.77819272999274;5.557565922504363;0.0012309330124483187;0.5744551915910391;[NIPBL, SGPL1]
GO:0043407;negative regulation of MAP kinase activity;12.0;0.811012628672052;0.8536266269261705;9.539970855150678;2610.1786565788484;5.4730085344763;0.08736033062741366;0.7280102235641875;[NUP62]
GO:0006783;heme biosynthetic process;7.0;0.8259837884571596;0.7639112594857803;9.464221201200845;646.2085211808783;6.781341354126479;0.02162801765401235;0.6977174774718518;[ATPIF1, CPOX]
GO:0006420;arginyl-tRNA aminoacylation;11.0;0.9326813400603323;0.8987696223598284;9.590783924509275;205.4345073903719;8.67846133901236;0.006875708083302461;0.8762458687964789;[RARS]
GO:0042795;snRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1410.6487555617684;5.528578385631111;0.047213144347195396;0.730852068336507;[CDK9, TBP, POLR2B, INTS3, INTS10, INTS4, POLR2G]
GO:0022900;electron transport chain;4.0;0.7140352122741334;0.6070176061370667;8.475844742553736;29.758801740447502;4.623782033182691;9.96000313069993E-4;0.48646042820481683;[NDUFB7, NDUFB10, NDUFS7, UQCRQ, NDUFS6, TXNRD1, COX4I1, NDUFA10, IDH3B, CYC1, COX5B]
GO:0006303;double-strand break repair via nonhomologous end joining;9.0;0.8933024483968273;0.8428918493787028;9.548481544818586;368.8093148901945;5.8067817141283475;0.012343715862540626;0.693199712083778;[DCLRE1C]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[HDAC3, HDAC1, ARID4A, DDX41, AATF, RLF, YY1, NIPBL, DPF2, EP300, SCAP, ZNF564, IER2, DR1, NCOA6, NFYC, PBX3, SENP2, FLI1, MED6, SETX, CDK9, TFCP2, NFIC, SP3, MTF2, TAF7]
GO:0051147;regulation of muscle cell differentiation;5.0;0.6023560406934092;0.5914190322076249;7.95454781892045;27.048145381022124;4.814228997420562;9.052770841523678E-4;0.5364409066735514;[ANKRD17, CDK9]
GO:0016236;macroautophagy;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;39.83166466328102;5.244474134527214;0.0013331299701091492;0.5584436629936305;[BECN1, CALCOCO2, C6orf106, DYNLL2]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[YY1, PSMD8, BECN1, VCPIP1, WDR48, PSMB1, USP39]
GO:1901097;negative regulation of autophagosome maturation;9.0;1.0;0.896240625180289;9.628524252492122;420.9901014208575;8.390779266560578;0.014090159828062918;0.8253454670833372;[CLEC16A]
GO:0045716;positive regulation of low-density lipoprotein particle receptor biosynthetic process;8.0;1.0;0.875;9.628524252492122;493.8377086675926;8.390779266560578;0.016528303684021042;0.8041048419030481;[SCAP]
GO:1904247;positive regulation of polynucleotide adenylyltransferase activity;6.0;1.0;0.8231203125901445;9.628524252492122;49.122279745261444;9.777073627680469;0.0016440784958923031;0.8231203125901445;[PABPN1]
GO:1901098;positive regulation of autophagosome maturation;9.0;1.0;0.896240625180289;9.628524252492122;490.39656958283985;7.8311634786251565;0.01641313185567848;0.7967266896635242;[CALCOCO2, CLEC16A]
GO:0006672;ceramide metabolic process;7.0;0.7140352122741334;0.7079369713942671;9.176539128749065;101.21355503378848;5.420364800990877;0.0033875266006951925;0.628117073252615;[SGPL1]
GO:0006307;DNA dealkylation involved in DNA repair;9.0;1.0;0.896240625180289;9.628524252492122;167.0562545400072;7.474488534686424;0.00559122249858591;0.7784863164434164;[ALKBH5]
GO:0030513;positive regulation of BMP signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.571365838652174;514.640204837359;6.311337724880743;0.017224544509792043;0.770882417347765;[FBXL15]
GO:0032933;SREBP signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;1530.9942493681936;7.8311634786251565;0.051240999720983706;0.8486063770733797;[SCAP]
GO:0051156;glucose 6-phosphate metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;72.82688802824934;6.686031174322154;0.0024374504023614934;0.6321649570480018;[G6PC3]
GO:0006669;sphinganine-1-phosphate biosynthetic process;8.0;1.0;0.875;9.628524252492122;655.390579785936;9.777073627680469;0.021935332892207386;0.875;[SPHK2]
GO:0010801;negative regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;780.3281191277907;7.069023426578259;0.026116879897493853;0.7767511986393403;[CALM1]
GO:0031848;protection from non-homologous end joining at telomere;9.0;1.0;0.896240625180289;9.628524252492122;217.09097804873235;7.8311634786251565;0.007265839666095271;0.7967266896635242;[DCLRE1C]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[CALM1]
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.537552474286395;374.7458266990886;5.54296712308321;0.012542405570270547;0.6584675964488075;[GLG1]
GO:0016226;iron-sulfur cluster assembly;5.0;0.6696747006330769;0.6250783621774587;8.347590407030058;61.314195544967326;6.7325511899570465;0.0020521309456966027;0.6345439928109722;[FAM96B]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[CLK1, ZMYM2, TRIM24, CLK4]
GO:0006361;transcription initiation from RNA polymerase I promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;6.311337724880743;0.015969835568764485;0.7190027299379095;[TBP]
GO:0006120;mitochondrial electron transport, NADH to ubiquinone;6.0;1.0;0.8231203125901445;9.628524252492122;32.64917349834284;5.9928839937622085;0.0010927384546410499;0.6295966787287501;[NDUFB7, NDUFB10, NDUFS7, NDUFS6, NDUFA10]
GO:1901142;insulin metabolic process;5.0;0.8933024483968273;0.736892236059334;9.405380701177911;47.85814540089318;7.8311634786251565;0.001601769057033345;0.6907270763441554;[ERN1]
GO:0006486;protein glycosylation;7.0;0.6181399273706679;0.6599893289425345;8.590536585640447;174.0766208890209;4.3090134865453384;0.005826187842367879;0.5712825153487487;[DPM3, COG3, SYVN1, TRAK1, GALNT10]
GO:0006123;mitochondrial electron transport, cytochrome c to oxygen;8.0;1.0;0.875;9.628524252492122;66.39695928536078;6.943860283624253;0.0022222464738971865;0.7301093378270707;[COX4I1, COX5B]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[TBP, NFYC, INTS3, INTS10, PBX3, ARID4A, FLI1, CDK9, TFCP2, POLR2B, NFIC, TRIM24, INTS4, EP300, LCOR, TAF7, POLR2G, IER2]
GO:0008543;fibroblast growth factor receptor signaling pathway;8.0;0.7090535922965819;0.729526796148291;8.567652291806858;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[SETX, POLR2B, POLR2G]
GO:0006363;termination of RNA polymerase I transcription;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;6.343086423195323;0.015969835568764485;0.7206263598461826;[TBP]
GO:0006122;mitochondrial electron transport, ubiquinol to cytochrome c;6.0;1.0;0.8231203125901445;9.628524252492122;32.64917349834284;7.138016298065211;0.0010927384546410499;0.6881587980249038;[UQCRQ, CYC1]
GO:1902236;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;10.0;0.9326813400603323;0.8815816818910864;9.596775554177542;830.7594506111926;6.832634648514029;0.02780477117699164;0.7646622655359331;[SYVN1]
GO:0006369;termination of RNA polymerase II transcription;9.0;0.8933024483968273;0.8428918493787028;9.5544162803384;477.15162764714074;6.139487467954083;0.015969835568764485;0.7102142998068259;[SETX, PABPN1, PCF11, CPSF2, SNRPG]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CDK9, TBP, POLR2B, TAF7, POLR2G, MED6]
GO:0006368;transcription elongation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;5.459585514144159;0.015969835568764485;0.675444082270312;[CDK9, POLR2B, POLR2G]
GO:0009755;hormone-mediated signaling pathway;5.0;0.6519675769143192;0.6162248003180799;7.98629651723503;23.17027026302992;4.61801832846594;7.75488093814194E-4;0.5264066839384828;[NCOA6, NUP62, TAF7]
GO:0098656;anion transmembrane transport;6.0;0.49195317825426244;0.5690969017172758;6.85593553025234;41.41505613938169;4.2676852910524925;0.0013861246578544264;0.541369936842231;[SLC25A3, SLC37A1, VDAC3, VDAC2]
GO:0098534;centriole assembly;5.0;0.8436909121759173;0.712086467948879;9.34084218004034;67.07652143820451;6.558197802812269;0.002244990807586635;0.6256275524841266;[NUP62]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[TLE4, GNG2, CSNK2A1, DVL3, SENP2, CALM1]
GO:0010613;positive regulation of cardiac muscle hypertrophy;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;95.57844489853944;6.444869117505266;0.003198924535738274;0.7045909063862833;[CDK9, BECN1, MTPN]
GO:0030100;regulation of endocytosis;6.0;0.5902001590945054;0.6182203921373972;8.152617732682543;44.90533409728707;4.321752512322768;0.0015029411200592913;0.5441349370523758;[RAB21, ATXN2, SYNJ1, SNX17, DOCK2]
GO:0017148;negative regulation of translation;8.0;0.6493065804076676;0.6996532902038338;9.081980546124052;1114.6737408694362;4.99795013456894;0.03730712696566269;0.6305954023103058;[EIF4ENIF1, CNOT1, TPR, CNOT10, EIF4E2, CNOT8]
GO:1904781;positive regulation of protein localization to centrosome;7.0;1.0;0.8509193652572005;9.628524252492122;73.70707873031733;7.9853141584524145;0.002466909593039506;0.7592887026755414;[NUP62]
GO:1901030;positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.604993755081928;568.8852724275073;6.311337724880743;0.01904007810464297;0.7190027299379095;[ATPIF1]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[SNAP29, DYNLL2]
GO:0006493;protein O-linked glycosylation;8.0;0.7140352122741334;0.7320176061370667;9.022388448921806;176.5615275388073;5.085725745451326;0.005909355431665436;0.6350842511328143;[DPM3, TRAK1, GALNT10]
GO:0006491;N-glycan processing;6.0;0.8436909121759173;0.7449657686781032;9.360260265897443;96.66964063832829;6.832634648514029;0.0032354458751365986;0.6725415662651573;[GNPTG, PRKCSH]
GO:0006370;7-methylguanosine mRNA capping;10.0;1.0;0.9152410118609203;9.628524252492122;354.47150569988446;6.250713103064308;0.011863842292131473;0.734902770639515;[POLR2B, POLR2G]
GO:0006013;mannose metabolic process;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;34.676020684410545;7.474488534686424;0.0011605752059146955;0.7053660038532718;[MAN2B2]
GO:0007223;Wnt signaling pathway, calcium modulating pathway;9.0;1.0;0.896240625180289;9.628524252492122;33.206889128170424;6.250713103064308;0.001111404694859899;0.7159023839588838;[GNG2, CALM1]
GO:0007100;mitotic centrosome separation;4.0;1.0;0.75;9.628524252492122;26.82333357677892;7.9853141584524145;8.977528353818361E-4;0.6583693374183408;[NUP62]
GO:1903214;regulation of protein targeting to mitochondrion;9.0;0.7980440201809971;0.7952626352707877;9.481920778300246;160.31632445447693;5.9928839937622085;0.005365643104166481;0.7027169913188946;[ATPIF1, PARL]
GO:1903578;regulation of ATP metabolic process;9.0;0.6547035408479693;0.7235923956042738;8.971744716103052;106.35464612672433;5.557565922504363;0.0035595942928941613;0.6804548049104079;[ATPIF1, ATP7A]
GO:0021860;pyramidal neuron development;7.0;1.0;0.8509193652572005;9.628524252492122;36.71755479978741;7.8311634786251565;0.0012289035154949403;0.7514054297404357;[UQCRQ, ATP7A]
GO:0006015;5-phosphoribose 1-diphosphate biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;251.39073302494668;7.9853141584524145;0.008413821597373791;0.7592887026755414;[PRPSAP1]
GO:0042744;hydrogen peroxide catabolic process;6.0;0.9326813400603323;0.7894609826203107;9.55953138100517;235.80375524332874;6.481236761676141;0.007892139478392308;0.6545710619905948;[PRDX1]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[HDAC3, HDAC1, NAB1, ARID4A, SMG5, GLG1, YY1, EIF4ENIF1, NIPBL, U2AF2, SAP130, TPR, DPF2, TRIM24, EP300, POLR2G, LRRFIP1, ZNF564, ZNF189, UPF2, TLE4, DR1, UBE2I, NFYC, CNOT10, SND1, ERN1, CDK9, CNOT6, PAN3, CNOT1, NFIC, PTRH2, SP3, MTF2, LCOR, TAF7, EIF4E2, CNOT8, DCP2]
GO:0032516;positive regulation of phosphoprotein phosphatase activity;10.0;0.8653626801206646;0.8479223519212526;9.5525383455142;1089.2705050571928;6.832634648514029;0.036456903524454846;0.7646622655359331;[CALM1]
GO:0030218;erythrocyte differentiation;5.0;0.8436909121759173;0.712086467948879;9.117698628726131;22.675663695230284;5.885253329569843;7.589340571069517E-4;0.5912131408273906;[SP3, ATPIF1]
GO:0019430;removal of superoxide radicals;5.0;1.0;0.7902410118609202;9.628524252492122;35.16553377750127;7.212124270218933;0.00117695876860726;0.659069382437994;[PRDX1, ATP7A]
GO:0098787;mRNA cleavage involved in mRNA processing;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;348.70325415094845;7.138016298065211;0.011670784103877944;0.7612791106150483;[ERN1]
GO:0018343;protein farnesylation;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;169.3659377599637;8.390779266560578;0.00566852551737791;0.8041048419030481;[FNTB]
GO:0032872;regulation of stress-activated MAPK cascade;10.0;0.7192862368539868;0.7748841302879137;9.350892515893841;234.58976921842068;4.411097612658618;0.007851508458655126;0.6408247489092991;[ERN1, HDAC3, KARS, PRDX1, DVL3, PAFAH1B1]
GO:0018107;peptidyl-threonine phosphorylation;9.0;0.7671156992804218;0.7797984748205;9.305750860229072;337.99482745314367;5.395046993006588;0.011312382699260763;0.6721435792979885;[CLK1, CSNK2A1]
GO:0043966;histone H3 acetylation;12.0;0.7671156992804218;0.8316781622303555;9.3498108500231;659.4528027923784;5.926926025970411;0.022071291840469662;0.7512235851885185;[POLE4, DR1]
GO:1902017;regulation of cilium assembly;8.0;0.7866048967936545;0.7683024483968273;9.34084218004034;85.2089877911262;5.926926025970411;0.002851868138258671;0.6781032725983739;[VDAC3, EVI5L]
GO:0006102;isocitrate metabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;48.4550644639303;8.16763571524637;0.001621747400880918;0.7686126355688037;[IDH3B, ACO2]
GO:1902018;negative regulation of cilium assembly;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;314.0650673358121;7.474488534686424;0.010511475163519584;0.7784863164434164;[EVI5L]
GO:0006346;methylation-dependent chromatin silencing;12.0;1.0;0.9481203125901445;9.628524252492122;1936.9706715625437;7.212124270218933;0.06482866521676948;0.8169486831672182;[HDAC1]
GO:0051225;spindle assembly;7.0;0.7508913569872202;0.7263650437508107;9.168991923113682;86.84099814437;5.266214121163619;0.00290649005606778;0.6202338003175094;[HDAC3, TUBGCP2, KPNB1, CLASP1]
GO:0051343;positive regulation of cyclic-nucleotide phosphodiesterase activity;6.0;1.0;0.8231203125901445;9.628524252492122;49.33745512692421;8.16763571524637;0.001651280222271285;0.7408135829017477;[CALM1]
GO:0032868;response to insulin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;4.800339885259895;0.0024778305216419678;0.5964089702280253;[SCAP]
GO:0010955;negative regulation of protein processing;9.0;0.7192862368539868;0.7558837436072825;9.27570287786938;707.1969765737138;6.039404009397101;0.023669246369964203;0.705096027081865;[GLG1]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[CSNK2A1, RFFL, SERPINB6]
GO:0032981;mitochondrial respiratory chain complex I assembly;7.0;1.0;0.8509193652572005;9.628524252492122;91.11357555959822;5.618190544320798;0.003049489377085438;0.638233890966345;[NDUFB7, NDUFA11, NDUFB10, NDUFS7, NDUFS6, NDUFA10]
GO:0016036;cellular response to phosphate starvation;7.0;1.0;0.8509193652572005;9.628524252492122;115.90251486529202;9.777073627680469;0.003879152867050031;0.8509193652572005;[COMT]
GO:0042407;cristae formation;7.0;1.0;0.8509193652572005;9.628524252492122;41.98985797947654;6.343086423195323;0.0014053627581543302;0.6753050999230941;[ATP5I, ATP5O, ATP5L]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[PHF3, NAB1, INTS10, ARID4A, CHD1, YY1, NIPBL, ZMYM2, SAP130, NUP62, DPF2, TRIM24, EP300, LRRFIP1, ZNF564, IER2, TLE4, TBP, CSNK2A1, COMMD3, ZFX, SND1, MED29, ERN1, LCOR, VGLL4, ZNF394, HDAC3, HDAC1, RLF, POLR2B, POLR2G, ZNF189, TRAPPC2, DR1, NFYC, INTS3, PBX3, CNOT10, FLI1, CDK9, CNOT6, TFCP2, CNOT1, NFIC, SP3, INTS4, TAF7, CNOT8]
GO:0006470;protein dephosphorylation;7.0;0.7586651285174919;0.7302519295159464;9.223059144383958;177.1697810635027;4.458953633836253;0.005929713129744359;0.5789504614541361;[PPP1CB, PTP4A1, PPP1CC, DUSP23, PTPRA, DUSP28, PPM1G]
GO:0007565;female pregnancy;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;5.299736813202263;0.0010979889214459554;0.4691490996802742;[SPHK2, COMT]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[NAB1, ARID4A, CIB1, DDX41, AATF, CHD1, YY1, NIPBL, ZMYM2, SAP130, NUP62, DPF2, TRIM24, EP300, LRRFIP1, FADS1, ZNF564, IER2, TLE4, TBP, CSNK2A1, NCOA6, ZFP91, COMMD3, SENP2, ZFX, SND1, MED6, MED29, TOX4, ERN1, THAP6, KARS, MTF2, LCOR, VGLL4, MTPN, ZNF394, HDAC3, HDAC1, TRAK1, RLF, TPR, DVL3, SCAP, ZNF189, TRAPPC2, DR1, UBE2I, NFYC, PBX3, CNOT10, FBXL15, FLI1, SETX, CDK9, CNOT6, TFCP2, CNOT1, GOLGB1, NFIC, SP3, TAF7, CNOT8]
GO:0007569;cell aging;3.0;0.7980440201809971;0.597142322680643;8.935377071932177;24.751975343904395;5.618190544320798;8.284263394289076E-4;0.485434838299289;[NUP62]
GO:0006359;regulation of transcription by RNA polymerase III;10.0;0.8436909121759173;0.837086467948879;9.52844079393514;248.56913769389934;6.481236761676141;0.008319385340914571;0.7466917612613706;[TBP]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[ZNF394, HDAC3, HDAC1, ARID4A, DDX41, AATF, TRAK1, CHD1, RLF, YY1, NIPBL, ZMYM2, SAP130, TPR, DPF2, EP300, SCAP, LRRFIP1, ZNF564, IER2, ZNF189, TLE4, DR1, UBE2I, TBP, NCOA6, NFYC, PBX3, ZFP91, FBXL15, SENP2, ZFX, FLI1, MED6, TOX4, SETX, CDK9, THAP6, TFCP2, CNOT1, NFIC, SP3, MTF2, LCOR, TAF7]
GO:0030433;ubiquitin-dependent ERAD pathway;10.0;0.9326813400603323;0.8815816818910864;9.600353375525426;603.0491029665483;5.557565922504363;0.02018351076733335;0.6994551915910392;[SYVN1]
GO:0006281;DNA repair;7.0;0.6281612110245125;0.6649999707694567;8.781226392104918;180.342582143442;3.582668236575797;0.006035903926554339;0.534137185486798;[AQR, WDR48, DCLRE1C, NCOA6, INTS3, CIB1, YY1, SETX, CDK9, NIPBL, POLR2B, EP300, POLR2G]
GO:0033540;fatty acid beta-oxidation using acyl-CoA oxidase;10.0;1.0;0.9152410118609203;9.628524252492122;581.3170730496397;7.069023426578259;0.019456159283571563;0.7767511986393403;[HSD17B4]
GO:0032330;regulation of chondrocyte differentiation;6.0;0.7671156992804218;0.7066781622303554;9.34084218004034;56.03372000150423;5.948432231191374;0.001875398181376348;0.6273234135236593;[GLG1]
GO:0006164;purine nucleotide biosynthetic process;9.0;0.6039883530135606;0.6982348016870694;8.853138973695204;1403.1328256552606;4.7018998124466425;0.04696159293712235;0.6366960002495126;[PRPSAP1, TPI1, ATP5I, CYC1, COX5B, ATP5O, ATP5L]
GO:0006282;regulation of DNA repair;7.0;0.6493065804076676;0.6755726554610344;8.81021392897817;104.86347213478491;5.123113277522946;0.003509686041353414;0.6129156165188555;[CDK9]
GO:0006283;transcription-coupled nucleotide-excision repair;9.0;1.0;0.896240625180289;9.628524252492122;184.43692670566384;5.486614186532078;0.006172937954381027;0.676826329833192;[AQR, POLR2B, EP300, POLR2G]
GO:0007257;activation of JUN kinase activity;14.0;1.0;0.9759193652572005;9.628524252492122;8640.54909511404;6.088194173566533;0.2891914022241413;0.7872698984233759;[ERN1]
GO:0009313;oligosaccharide catabolic process;5.0;0.6763753087927167;0.6284286662572787;8.458452999841867;68.60352119966694;7.069023426578259;0.0022960981153922187;0.6517511986393402;[MAN2B2]
GO:0008344;adult locomotory behavior;3.0;0.8436909121759173;0.6199657686781032;9.158520623246385;24.575257889458463;5.459585514144159;8.225117652639858E-4;0.47732376968016754;[PBX3, PAFAH1B1, ARCN1]
GO:0042135;neurotransmitter catabolic process;5.0;0.7248374789738407;0.6526597513478406;8.795615129557017;61.24086206619916;6.599019797332524;0.0020496765401580783;0.6277151911823093;[COMT]
GO:0022400;regulation of rhodopsin mediated signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;59.729069814557675;6.641579411751319;0.0019990782140203315;0.6905700452391912;[CALM1]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[TLE4, DR1, UBE2I, HDAC3, HDAC1, NAB1, NFYC, ARID4A, YY1, NIPBL, CNOT1, NFIC, SAP130, TPR, SP3, MTF2, DPF2, TRIM24, EP300, LCOR, TAF7, LRRFIP1, ZNF564, ZNF189]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[HDAC3, HDAC1, ARID4A, DDX41, AATF, RLF, YY1, NIPBL, NUP62, DPF2, TRIM24, DVL3, EP300, SCAP, ZNF564, IER2, DR1, TBP, NCOA6, NFYC, PBX3, SENP2, FLI1, MED6, SETX, CDK9, TFCP2, KARS, NFIC, SP3, MTF2, TAF7]
GO:0017187;peptidyl-glutamic acid carboxylation;9.0;1.0;0.896240625180289;9.628524252492122;309.49489246412384;8.67846133901236;0.010358515523454532;0.8400575416471059;[VKORC1]
GO:0018279;protein N-linked glycosylation via asparagine;9.0;0.8653626801206646;0.8289219652406215;9.4949928598676;334.83267440717236;6.113511981550823;0.011206548282565083;0.7088859122241795;[SYVN1]
GO:0030149;sphingolipid catabolic process;7.0;0.7586651285174919;0.7302519295159464;9.31486669363708;277.9336559378963;6.558197802812269;0.009302189340190472;0.6863059058804069;[SGPL1]
GO:0030148;sphingolipid biosynthetic process;7.0;0.6913464685778243;0.6965925995461126;8.992535485772125;238.8284648682076;5.288437257948329;0.007993373787475071;0.6213702925661609;[SGPL1, ELOVL5, SPHK2]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[KCNK6, SLC9A6]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[HDAC1, EP300, CIB1]
GO:0042267;natural killer cell mediated cytotoxicity;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;47.356962503066434;6.7325511899570465;0.001584994916478408;0.6674232935401965;[PRDX1]
GO:0009443;pyridoxal 5'-phosphate salvage;8.0;0.9326813400603323;0.8413406700301662;9.606545345773347;1144.8986362947817;9.777073627680469;0.03831872701490913;0.875;[PDXK]
GO:1901911;adenosine 5'-(hexahydrogen pentaphosphate) catabolic process;11.0;1.0;0.9324289523296623;9.628524252492122;7788.754996508613;8.390779266560578;0.2606826203087368;0.8615337942327104;[NUDT3]
GO:1901907;diadenosine pentaphosphate catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;1524.883104835901;8.390779266560578;0.05103646521316088;0.8443458537639685;[NUDT3]
GO:0045541;negative regulation of cholesterol biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;666.1065498284223;8.16763571524637;0.02229398676578249;0.8329342821725234;[SCAP]
GO:0019353;protoporphyrinogen IX biosynthetic process from glutamate;11.0;1.0;0.9324289523296623;9.628524252492122;1118.184659315538;9.777073627680469;0.03742463424643226;0.9324289523296623;[CPOX]
GO:1901909;diadenosine hexaphosphate catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;1524.883104835901;8.390779266560578;0.05103646521316088;0.8443458537639685;[NUDT3]
GO:0033762;response to glucagon;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;6.166155715036245;0.0024778305216419678;0.6662568552797195;[CYC1]
GO:0032436;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;11.0;0.8259837884571596;0.845420846558242;9.498471124243924;3778.5456327194074;5.334422371190153;0.12646452185682636;0.705231560468336;[ZFAND2A]
GO:0032435;negative regulation of proteasomal ubiquitin-dependent protein catabolic process;11.0;0.8436909121759173;0.8542744084176208;9.523163736834295;3784.4609618058316;6.343086423195323;0.1266625025978984;0.7568146869955557;[CLEC16A]
GO:0006383;transcription by RNA polymerase III;10.0;0.8436909121759173;0.837086467948879;9.499312521012115;583.8786478812184;6.113511981550823;0.01954189288791682;0.7278862989048107;[TBP]
GO:0045665;negative regulation of neuron differentiation;8.0;0.6162540371078848;0.6831270185539424;8.732436227935485;338.1488864638422;4.401795219996305;0.011317538915704735;0.6001080122550225;[EIF4ENIF1, CIB1, PAFAH1B1]
GO:0008203;cholesterol metabolic process;6.0;0.7980440201809971;0.722142322680643;9.223059144383958;82.64786032185484;5.058574756385375;0.0027661495067272364;0.581816060879476;[SNX17, SCAP]
GO:0038095;Fc-epsilon receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.989581884898423;0.002626513627734276;0.6301674496329921;[CALM1]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[ANKRD17, UBE2I, NUP62]
GO:0046512;sphingosine biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;656.7339991758098;7.474488534686424;0.021980295930187507;0.7784863164434164;[SPHK2]
GO:0045787;positive regulation of cell cycle;5.0;0.5265193887476639;0.5535007062347522;7.230628979693751;42.184038669436575;3.8238302933926853;0.0014118618110960173;0.4857918708913159;[ANKRD17, BECN1, CNOT10, ANAPC11, CDK9, CNOT6, NIPBL, SPAST, CNOT1, TPR, FNTB, NUP62, CASP2, EP300, PKP4, ANAPC5, CNOT8, PAFAH1B1]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[ERN1, SGPL1, DPF2, CASP2, EP300, CIB1, KRCC1]
GO:0043248;proteasome assembly;6.0;0.8653626801206646;0.7558016526504768;9.310070521373587;44.51706700895919;7.138016298065211;0.0014899461700306506;0.6881587980249038;[PSMD8]
GO:0048813;dendrite morphogenesis;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;64.60914726719044;6.063501560976162;0.0021624100145753813;0.6850877518099798;[TRAK1]
GO:0031338;regulation of vesicle fusion;6.0;0.7248374789738407;0.6855390520770648;8.935377071932177;48.20117096329211;5.514393750639154;0.0016132498139038735;0.6051266654433651;[VPS18, RABGAP1, VPS41, EVI5L, TBC1D22A]
GO:2000811;negative regulation of anoikis;8.0;1.0;0.875;9.628524252492122;103.9210822679579;6.943860283624253;0.0034781451006065307;0.7301093378270707;[PTRH2]
GO:0010638;positive regulation of organelle organization;6.0;0.4793097133439409;0.562775169262115;6.85593553025234;66.93492229097139;3.4123228708285582;0.0022402516115597013;0.49762666289355856;[BECN1, TMED9, PDCD6IP, CALCOCO2, WIPF2, ATPIF1, CLEC16A, IQGAP2, ANAPC11, CDK9, CNOT6, NIPBL, PAN3, SYNJ1, CNOT1, TPR, NUP62, MTF2, ANAPC5, CLASP1]
GO:0016197;endosomal transport;5.0;0.7090535922965819;0.6447678080092112;8.817594036275793;47.18803257139101;4.463867648638682;0.0015793409836922997;0.5185234110033771;[ALS2, SNX17, CLEC16A]
GO:0032543;mitochondrial translation;8.0;1.0;0.875;9.628524252492122;403.65714686199146;6.193554689224359;0.013510041437624024;0.6917386748366816;[MRPS18A]
GO:0035814;negative regulation of renal sodium excretion;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;135.80387696814384;8.390779266560578;0.004545233546569409;0.8041048419030481;[COMT]
GO:0010870;positive regulation of receptor biosynthetic process;7.0;0.8436909121759173;0.7727648213451592;9.466005322994347;258.61903890750995;7.379178354882098;0.008655746490210232;0.728290889492758;[HDAC1, SCAP]
GO:0070979;protein K11-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;6.375876246018314;0.00527474598481953;0.7584915600596062;[ANAPC5, ANAPC11]
GO:0008210;estrogen metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;78.56989776551285;6.599019797332524;0.002629663769894499;0.6605944919115335;[SGPL1, HSD17B4, COMT]
GO:0032780;negative regulation of ATPase activity;6.0;0.7508913569872202;0.6985659910837546;8.781226392104918;51.329885291612335;7.004484905440688;0.0017179650668126642;0.6813299963962409;[ATPIF1]
GO:0008334;histone mRNA metabolic process;8.0;0.8653626801206646;0.8076813400603323;9.510741216835738;116.87339225437435;6.558197802812269;0.0039116472595296945;0.7103865406232063;[CPSF2, SNRPG, DCP2]
GO:0008333;endosome to lysosome transport;6.0;0.8436909121759173;0.7449657686781032;9.36615998802463;62.67584315854233;5.769740442447999;0.0020977040659196657;0.618185107137305;[VPS18, VPS41, CLEC16A, TRAK1]
GO:0006397;mRNA processing;8.0;0.7140352122741334;0.7320176061370667;9.165900730544008;234.3529203123214;3.6745150330669007;0.00784358133891816;0.5629148696734654;[TRUB2, SF3B5, SF3B2, AHCYL1, DDX42, DDX41, USP39, EFTUD2, ALKBH5, PABPN1, PCF11, U2AF2, POLR2B, ARL6IP4, SNRPB2, POLR2G, SMNDC1, AQR, GPKOW, CPSF2, SRRM1, ERN1, PAN3, FASTKD5, SNRPG, SLU7]
GO:0008209;androgen metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;78.56989776551285;6.444869117505266;0.002629663769894499;0.6527112189764278;[SGPL1, HSD17B4]
GO:0016180;snRNA processing;9.0;0.7980440201809971;0.7952626352707877;9.354087406790361;356.38664419027253;6.221725566191056;0.01192794025389202;0.7144199599751273;[INTS3, INTS10, INTS4]
GO:0016062;adaptation of rhodopsin mediated signaling;7.0;1.0;0.8509193652572005;9.628524252492122;43.237532372156394;9.083926447120524;0.001447121297243272;0.8154717862087246;[RDH11]
GO:0001934;positive regulation of protein phosphorylation;9.0;0.5833093054345528;0.6878952778975655;8.604019935977734;663.1129447749842;2.9039097934679514;0.02219379349871355;0.5447467070638558;[ERN1, CDK9, HDAC3, KARS, ALS2, DVL3, ZFP91, CIB1, SENP2, CALM1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[DOCK8, GLG1]
GO:0001937;negative regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.36028873802138;6.193554689224359;0.002923870244906099;0.6676580400938822;[ATPIF1]
GO:0035924;cellular response to vascular endothelial growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;62.59148538135601;6.599019797332524;0.00209488068703431;0.6605944919115335;[ERN1]
GO:0010761;fibroblast migration;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;22.57397290845719;7.474488534686424;7.555305579894227E-4;0.7053660038532718;[SGPL1]
GO:0010881;regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion;11.0;1.0;0.9324289523296623;9.628524252492122;219.4584201917244;6.8867018697843045;0.007345075824061613;0.7846152062148197;[CALM1]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[ERN1, PPM1G]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[SF3B5, AQR, SF3B2, GPKOW, CPSF2, DDX42, DDX41, USP39, SRRM1, EFTUD2, ERN1, PABPN1, PCF11, U2AF2, POLR2B, SNRPG, ARL6IP4, SNRPB2, POLR2G, SLU7, SMNDC1]
GO:0007052;mitotic spindle organization;7.0;0.8259837884571596;0.7639112594857803;9.280217558223907;96.21539173928952;5.486614186532078;0.0032202425732832385;0.6315050699101035;[SPAST, TUBGCP2, TBCE, KPNB1, CLASP1]
GO:0042572;retinol metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;118.00963323224862;6.375876246018314;0.003949676222508656;0.722303232910233;[RDH11]
GO:0045963;negative regulation of dopamine metabolic process;8.0;0.9326813400603323;0.8413406700301662;9.574457031221845;288.50442548003474;8.390779266560578;0.0096559834836909;0.8041048419030481;[COMT]
GO:0045842;positive regulation of mitotic metaphase/anaphase transition;11.0;0.9326813400603323;0.8987696223598284;9.60254876608886;1435.6381372244598;7.57984905034425;0.04804951646246229;0.8200627852632958;[ANAPC5, ANAPC11]
GO:0051170;import into nucleus;7.0;0.7436939687323844;0.7227663496233927;8.935377071932177;33.8974465615721;5.076593261888053;0.001134517030694512;0.6105365807558851;[TPR, NUP62, RAB18, SNRPG, NUP153, TNPO2, KPNB1]
GO:0042574;retinal metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;79.50217411028933;7.212124270218933;0.0026608662201599294;0.7650689957573628;[RDH11]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[BECN1, NIPBL, NUP62, ANAPC5, ANAPC11]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RIC8A, RABGAP1, ALS2, DOCK8, DVL3, PKP4, EVI5L, DOCK2, TBC1D22A]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[ATPIF1]
GO:0035999;tetrahydrofolate interconversion;8.0;1.0;0.875;9.628524252492122;262.53585291497376;7.292166977892469;0.008786838730136297;0.747921758369865;[ATPIF1]
GO:0031397;negative regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;529.4632463014641;5.572381008289503;0.01772065836772442;0.7002128357670632;[GNL3L, U2AF2, SENP2]
GO:0032008;positive regulation of TOR signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;6.250713103064308;0.008002824611389124;0.6946617587785947;[HDAC3, CLEC16A]
GO:0090305;nucleic acid phosphodiester bond hydrolysis;6.0;0.6073376606709605;0.6267891429256247;8.355558576679234;112.24841944109592;4.100319825412187;0.0037568535816745637;0.5328108591460956;[DCLRE1C, CPSF2, SMG5, SND1, ERN1, CNOT6, PAN3, CNOT1, PCF11, RPP21, CNOT8, DCP2, KPNB1]
GO:0006094;gluconeogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;174.6088252776196;5.926926025970411;0.005844000244301424;0.6540226378555745;[TPI1, G6PC3]
GO:1904263;positive regulation of TORC1 signaling;9.0;1.0;0.896240625180289;9.628524252492122;286.95354203151174;7.57984905034425;0.009604076810373322;0.7838744581139225;[CLEC16A]
GO:1903052;positive regulation of proteolysis involved in cellular protein catabolic process;9.0;0.7508913569872202;0.7716863036738992;9.392135474427892;1434.765180146359;4.973052582947213;0.04802029937466862;0.6505627655428052;[ZFAND2A, ATPIF1]
GO:0030183;B cell differentiation;6.0;0.7307253602413294;0.6884829927108091;9.022388448921806;64.35544597283358;5.2552850506314295;0.0021539188605695985;0.5918758344751833;[DCLRE1C, SP3, EP300]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[RIC8A, AHCYL1, GNG2, SPHK2, IQGAP2, CALM1]
GO:0030182;neuron differentiation;4.0;0.5833093054345528;0.5416546527172764;7.212610474191073;21.066225782797595;4.296434704338478;7.050676185779127E-4;0.4697198705845162;[MTPN, PPP1CC, HERC1, ATP7A, IER2, PAFAH1B1]
GO:0033572;transferrin transport;10.0;1.0;0.9152410118609203;9.628524252492122;96.80640656383476;6.193554689224359;0.0032400233075819585;0.731979686697602;[ATP6V1F]
GO:0061086;negative regulation of histone H3-K27 methylation;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;804.8473500351352;8.390779266560578;0.026937516490087493;0.8615337942327104;[MTF2]
GO:0061087;positive regulation of histone H3-K27 methylation;11.0;0.9326813400603323;0.8987696223598284;9.59953671561887;804.0422852806381;7.9853141584524145;0.026910571697265715;0.8407982897480031;[MTF2]
GO:0045732;positive regulation of protein catabolic process;7.0;0.7043150770688792;0.7030769037916401;9.033817144745429;231.0521549826792;4.39257856489138;0.0077331076938309705;0.5755560373415389;[CSNK2A1, ZFAND2A, ATPIF1]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[PDXK, TMEM30A, PSMB1, RAB18, COMMD3, DOCK2, IQGAP2, SNAP29, KPNB1, SERPINB6]
GO:0006099;tricarboxylic acid cycle;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;83.50034911327728;6.250713103064308;0.0027946815393860435;0.6946617587785947;[CS, IDH3B, ACO2]
GO:0046822;regulation of nucleocytoplasmic transport;6.0;0.6547035408479693;0.6504720830141292;8.529911963824013;30.746838917960506;5.040875179285974;0.0010290690282256237;0.5809109036834981;[PPP1CC, HDAC3, TPR, NUP62, NUP153]
GO:1990579;peptidyl-serine trans-autophosphorylation;11.0;1.0;0.9324289523296623;9.628524252492122;706.4377701929016;9.777073627680469;0.023643836415639802;0.9324289523296623;[ERN1]
GO:0031145;anaphase-promoting complex-dependent catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;350.55619955642163;6.221725566191056;0.011732800519056534;0.7334203466557586;[ANAPC5, ANAPC11]
GO:0015914;phospholipid transport;7.0;0.7763722522362496;0.7391054913753253;9.040737587590003;67.00175910617337;5.618190544320798;0.0022424885796152832;0.638233890966345;[TMEM30A, PITPNB]
GO:0031146;SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;350.55619955642163;6.063501560976162;0.011732800519056534;0.7253287636709003;[FBXL3, FBXL15]
GO:0030177;positive regulation of Wnt signaling pathway;7.0;0.7307253602413294;0.7162820453778652;9.040737587590003;188.4547261984632;4.948759890378168;0.006307410087620234;0.6039991761920099;[CSNK2A1]
GO:0033327;Leydig cell differentiation;4.0;1.0;0.75;9.628524252492122;40.68519770516384;7.379178354882098;0.0013616969528911006;0.6273715242355574;[SGPL1]
GO:1904380;endoplasmic reticulum mannose trimming;10.0;0.8436909121759173;0.837086467948879;9.446202695698167;249.61615283182627;7.004484905440688;0.008354427995328538;0.7734506956670166;[SYVN1]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CFDP1, WIPF2]
GO:0007270;neuron-neuron synaptic transmission;8.0;1.0;0.875;9.628524252492122;25.73829654599903;7.8311634786251565;8.61437622431563E-4;0.7754860644832351;[VDAC3]
GO:0090630;activation of GTPase activity;7.0;1.0;0.8509193652572005;9.628524252492122;49.337455126924546;5.2552850506314295;0.0016512802222712962;0.6196748871422394;[RABGAP1, EVI5L, TBC1D22A]
GO:0045742;positive regulation of epidermal growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;233.1839134473908;6.280566066213989;0.0078044557311868065;0.6961884407023742;[NUP62]
GO:0046835;carbohydrate phosphorylation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;67.30508528847182;6.518977089658987;0.002252640633960971;0.6565011041187423;[GNPTG]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[PSMD8, PRKCSH, PSMB1, FBXL3, FBXL15]
GO:0046834;lipid phosphorylation;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;69.34085176665127;4.948759890378168;0.0023207759059147553;0.5762001235249539;[SPHK2]
GO:0032465;regulation of cytokinesis;6.0;0.5930994877375815;0.6196700564589352;8.140447197062288;31.798591743249187;5.358233019883872;0.0010642702487719462;0.5971405984103235;[BECN1, SPAST, NUP62, PKP4, CALM1]
GO:0034765;regulation of ion transmembrane transport;6.0;0.45556283921517005;0.5509017321977295;6.676594601596523;33.03735142972539;3.697140432584879;0.0011057304206669666;0.512192246247148;[KCNK6, AHCYL1, ATP7A, CALM1]
GO:0035735;intraciliary transport involved in cilium assembly;8.0;1.0;0.875;9.628524252492122;77.80597868627544;6.088194173566533;0.0026040960857949586;0.6863505331661754;[DYNLL2]
GO:0032467;positive regulation of cytokinesis;7.0;0.7043150770688792;0.7030769037916401;9.015419779605713;142.0565341908292;6.193554689224359;0.004754504356786525;0.6676580400938822;[SPAST, NUP62, PKP4]
GO:0070816;phosphorylation of RNA polymerase II C-terminal domain;11.0;0.811012628672052;0.8379352666656883;9.52844079393514;433.3999751397635;7.8311634786251565;0.014505507133273452;0.8329150168128974;[CDK9]
GO:0035970;peptidyl-threonine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.004484905440688;0.005999310166768488;0.7332096838060964;[PPM1G]
GO:0070936;protein K48-linked ubiquitination;11.0;1.0;0.9324289523296623;9.628524252492122;157.60047254366168;5.8650506222523235;0.00527474598481953;0.7323679139043926;[SYVN1, RFFL]
GO:0007043;cell-cell junction assembly;5.0;0.7508913569872202;0.6656866903545304;8.817594036275793;53.94372379865016;5.16195311083921;0.0018054478893412883;0.554223534004606;[PDCD6IP, PKP4]
GO:0030163;protein catabolic process;5.0;0.6347111282356054;0.607596575978723;8.35223078658656;135.66522553384723;3.7109655375767217;0.004540593007841691;0.48001996203013964;[UBE2I, RNF38, SYVN1, CLTA, FBXL15, ANAPC11, PSMD8, KBTBD4, KCTD10, PSMB1, TRIM24, FBXL3, ANAPC5, RFFL, C18orf25]
GO:0046601;positive regulation of centriole replication;11.0;0.9326813400603323;0.8987696223598284;9.592156608321247;492.4861511887348;8.67846133901236;0.016483068271526433;0.8762458687964789;[NUP62]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[TLE4, CAMLG, CSNK2A1, WIPF2, CIB1, SENP2, SETX, SGPL1, GNG2, KARS, SLC9A6, PTPRA, POLR2B, NUP62, DVL3, CASP2, EP300, POLR2G, CALM1, ATP6V1F]
GO:0031124;mRNA 3'-end processing;9.0;0.8436909121759173;0.8180860812682478;9.52844079393514;355.1646528804444;5.407625775213448;0.011887041304472852;0.6727868588050205;[AHCYL1, PABPN1, PCF11, U2AF2, CPSF2, SLU7, SRRM1]
GO:0070933;histone H4 deacetylation;10.0;0.8933024483968273;0.861892236059334;9.548481544818586;358.70493891627973;7.57984905034425;0.012005531492041683;0.8028748447945538;[HDAC1]
GO:0071902;positive regulation of protein serine/threonine kinase activity;11.0;0.6763753087927167;0.7706166067260205;9.206529842432747;1260.5827351979337;3.9422628906178643;0.04219056969626795;0.6340364598898325;[ERN1, KARS, ALS2, DVL3, CIB1, CALM1]
GO:0070932;histone H3 deacetylation;10.0;0.8653626801206646;0.8479223519212526;9.510741216835738;358.70493891627973;6.781341354126479;0.012005531492041683;0.7620391240755716;[HDAC3, HDAC1]
GO:0007098;centrosome cycle;4.0;1.0;0.75;9.628524252492122;37.692070457630365;6.088194173566533;0.0012615196775557923;0.5613505331661754;[NUP62]
GO:0009396;folic acid-containing compound biosynthetic process;7.0;0.8259837884571596;0.7639112594857803;9.525870098432039;991.1210210799227;7.292166977892469;0.033171928624536405;0.7238411236270654;[ATPIF1]
GO:0022008;neurogenesis;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.572381008289503;7.050676185779127E-4;0.5349718239061428;[TRAK1]
GO:0060766;negative regulation of androgen receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;234.23542340630428;7.292166977892469;0.007839648823214116;0.747921758369865;[HDAC1]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[BECN1, ALKBH5, EP300, ITPR2, SCAP, ATP7A, TM9SF4]
GO:0046580;negative regulation of Ras protein signal transduction;9.0;0.8259837884571596;0.8092325194088689;9.394909401310617;288.24654468039586;5.885253329569843;0.009647352445404638;0.6972127541467594;[NUP62]
GO:0070562;regulation of vitamin D receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;60.37776523254894;7.9853141584524145;0.0020207894658725253;0.7592887026755414;[TRIM24]
GO:0010259;multicellular organism aging;4.0;0.9326813400603323;0.7163406700301662;9.474373572664863;29.177677042081047;6.943860283624253;9.765505923939418E-4;0.6051093378270707;[NDUFS6]
GO:0071897;DNA biosynthetic process;7.0;0.7090535922965819;0.7054461614054914;9.249034630787218;573.3007402310989;5.058574756385375;0.01918785983836615;0.609615113546532;[POLE4, SMG5]
GO:0070208;protein heterotrimerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;7.212124270218933;0.002859955186148837;0.7197477358342742;[NUP62]
GO:0035435;phosphate ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;110.11210983553856;7.138016298065211;0.003685353221730381;0.7400384854347593;[SLC25A3, SLC37A1]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[PRKCSH, DOCK8, CLEC16A, ITPR2, KRCC1, RAB21, GNG2, PABPN1, DVL3, CASP2, EP300, STK38L, CNOT10, SETX, ERN1, CNOT6, SNRK, KARS, ALS2, PTPRA, CNOT1, RAB18, DOCK2, CNOT8, CALM1, KPNB1, EXOC1]
GO:0035553;oxidative single-stranded RNA demethylation;9.0;1.0;0.896240625180289;9.628524252492122;151.67934936050318;8.67846133901236;0.005076571320544113;0.8400575416471059;[ALKBH5]
GO:0034220;ion transmembrane transport;5.0;0.44800904580126355;0.514245534761552;6.183841758890227;26.332710660334534;2.96803432163749;8.813321279004005E-4;0.4420264250971726;[SLC30A7, KCNK6, SLC25A3, SLC37A1, COX4I1, ITPR2, ATP5I, COX5B, ATP5O, ATP5L, SLC9A6, NDUFS7, VDAC3, VDAC2, CYC1, ATP7A, CALM1, ATP6V1F]
GO:1902600;proton transmembrane transport;8.0;0.7586651285174919;0.754332564258746;9.117698628726131;95.86613314633948;4.835431205071165;0.0032085532024895276;0.6222841766978864;[SLC25A3, SLC9A6, NDUFS7, COX4I1, ATP5I, CYC1, COX5B, ATP5O, ATP5L, ATP6V1F]
GO:0000226;microtubule cytoskeleton organization;5.0;0.579397892394798;0.5799399580583193;7.662411396119289;30.307791186580253;3.8212362582156385;0.0010143744957736317;0.4856592118117268;[NIN, SPAST, HDAC3, TUBGCP2, TBCE, CIB1, VAMP4, CALM1, KPNB1, CLASP1, PAFAH1B1]
GO:0001682;tRNA 5'-leader removal;11.0;1.0;0.9324289523296623;9.628524252492122;715.7997923127639;7.474488534686424;0.023957174870718703;0.8146746435927894;[RPP21]
GO:0033365;protein localization to organelle;5.0;0.5041090598531663;0.5422955417875035;7.010086210079599;29.829169826127035;3.3522046037750814;9.983554695705216E-4;0.46167291119143417;[PEX16, BECN1, TMEM30A, PEX19, COG3, HSD17B4, NUP153, AP3M1, NIPBL, GOLGB1, VPS41, NUP62, TNPO2, KPNB1]
GO:0033129;positive regulation of histone phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1473.5624568792941;7.697632086000634;0.04931880931163779;0.8088982747154926;[CDK9]
GO:0055074;calcium ion homeostasis;8.0;0.6302958089695718;0.6901479044847859;8.465373442686442;72.15273857439408;3.748795107449771;0.0024148872268360765;0.5667135561317821;[TRIM24, ITPR2, CALM1]
GO:0008286;insulin receptor signaling pathway;8.0;0.8653626801206646;0.8076813400603323;9.34084218004034;31.002284443533863;5.346256828837156;0.0010376185600805164;0.6484078228531001;[PTPRA, ATP6V1F]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[BECN1, KARS, FNTB, NUP62, ATPIF1, TRIM24, CIB1, EMP3, CNOT8, COMT]
GO:0033120;positive regulation of RNA splicing;8.0;0.8933024483968273;0.8216512241984136;9.584072489921288;456.71654511042715;6.221725566191056;0.015285891746640958;0.6931793347948383;[SETX, ERN1, U2AF2]
GO:0032272;negative regulation of protein polymerization;7.0;0.7763722522362496;0.7391054913753253;9.223059144383958;115.24641674738749;5.587418885654044;0.003857193853493737;0.6366602269110988;[VDAC2]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[ERN1, PPP1CC, CNOT6, WDR48, CSNK2A1, SPHK2, HDAC1, FNTB, CIB1, ATP7A, CNOT8]
GO:1901525;negative regulation of mitophagy;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;765.9069832582293;7.9853141584524145;0.0256342174581193;0.8046099625986299;[CLEC16A]
GO:0001522;pseudouridine synthesis;8.0;0.7980440201809971;0.7740220100904985;9.370695143190021;132.84444565068281;6.8867018697843045;0.004446184043689257;0.7271862538851576;[TRUB2]
GO:0070584;mitochondrion morphogenesis;5.0;1.0;0.7902410118609202;9.628524252492122;64.70445744698846;6.781341354126479;0.002165599960519628;0.6370391240755715;[NDUFS6]
GO:0048662;negative regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.58586787906956;5.970411137910149;0.0021281617743466354;0.6284474158353811;[COMT]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[HSD17B4, SND1]
GO:0031297;replication fork processing;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;150.6515651586252;6.375876246018314;0.005042172308252987;0.701062607729944;[CDK9]
GO:0000209;protein polyubiquitination;10.0;0.7671156992804218;0.7987988615011312;9.223059144383958;155.4032479663248;4.243684138952949;0.005201206855589802;0.6322632160784685;[SYVN1, ZFP91, FBXL3, ANAPC5, FBXL15, RFFL, C18orf25, ANAPC11]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[BECN1, CLEC16A, COMT, FADS1]
GO:0048666;neuron development;4.0;0.6696747006330769;0.5848373503165385;8.088079211544972;32.15320660831846;4.814228997420562;0.001076138889173156;0.4961998948126311;[BECN1, UQCRQ, PBX3, ATP7A, PAFAH1B1]
GO:1904925;positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization;9.0;0.8653626801206646;0.8289219652406215;9.566003895510788;478.9710975949461;7.292166977892469;0.016030731590500887;0.769162383550154;[ATPIF1]
GO:0001662;behavioral fear response;5.0;1.0;0.7902410118609202;9.628524252492122;37.889479621082295;6.375876246018314;0.0012681267845998157;0.6163036195908642;[ALS2, VDAC3]
GO:1990830;cellular response to leukemia inhibitory factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[TLE4, MTF2]
GO:0048311;mitochondrion distribution;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;32.547621880228036;6.943860283624253;0.00108933961337327;0.6453503496879909;[TRAK1]
GO:0034314;Arp2/3 complex-mediated actin nucleation;13.0;1.0;0.9625549647676366;9.628524252492122;481.965084327204;6.599019797332524;0.016130937632016437;0.8000291440890255;[IQGAP2]
GO:0031047;gene silencing by RNA;8.0;0.7671156992804218;0.7585578496402109;9.168991923113682;70.59795582467933;5.885253329569843;0.002362850047416754;0.6759721289664703;[CNOT6, CNOT1, CNOT10, CNOT8, SND1]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[PABPN1, COMT]
GO:0071544;diphosphoinositol polyphosphate catabolic process;8.0;1.0;0.875;9.628524252492122;359.1661571393407;9.777073627680469;0.012020968050898084;0.875;[NUDT3]
GO:0007080;mitotic metaphase plate congression;7.0;1.0;0.8509193652572005;9.628524252492122;61.63195576956532;6.193554689224359;0.002062766094448262;0.6676580400938822;[BECN1, NUP62, KPNB1]
GO:0071426;ribonucleoprotein complex export from nucleus;10.0;0.7866048967936545;0.8085434602577476;9.420884887713877;216.78685677046144;6.781341354126479;0.007255661000602924;0.7620391240755716;[NUP62]
GO:0015991;ATP hydrolysis coupled proton transport;10.0;1.0;0.9152410118609203;9.628524252492122;157.7498630086325;6.375876246018314;0.005279745949239413;0.7413036195908642;[ATP6V1F]
GO:0015990;electron transport coupled proton transport;10.0;1.0;0.9152410118609203;9.628524252492122;98.35103979612603;8.390779266560578;0.0032917207917870896;0.8443458537639685;[NDUFS7]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[CLK1, ERN1, TRIM24, CLK4]
GO:0042059;negative regulation of epidermal growth factor receptor signaling pathway;8.0;0.8436909121759173;0.7968454560879586;9.417215158824915;234.05310184950287;6.113511981550823;0.00783354668478672;0.6876452870438905;[NUP62]
GO:0046778;modification by virus of host mRNA processing;9.0;0.8933024483968273;0.8428918493787028;9.590783924509275;172.12234018819666;9.083926447120524;0.005760779826049735;0.8607930461318132;[PABPN1]
GO:0060964;regulation of gene silencing by miRNA;8.0;0.7369933605727446;0.7434966802863723;9.158520623246385;63.198578554006836;5.8067817141283475;0.0021151995491745495;0.6719590869034888;[POLR2B, POLR2G]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[CSNK2A1, RFFL]
GO:0006914;autophagy;4.0;0.6729672293956388;0.5864836146978194;8.39638057119949;37.75222312160081;4.39717627414001;0.001263532933085;0.4748717991491287;[VPS18, BECN1, CALCOCO2, VPS41, CLEC16A, C6orf106, DYNLL2]
GO:0043153;entrainment of circadian clock by photoperiod;6.0;1.0;0.8231203125901445;9.628524252492122;32.762264927729;6.686031174322154;0.001096523523006926;0.665044257777226;[PPP1CB, PPP1CC, FBXL3]
GO:0016973;poly(A)+ mRNA export from nucleus;10.0;1.0;0.9152410118609203;9.628524252492122;122.0533615230405;7.004484905440688;0.004085016169282269;0.7734506956670166;[PABPN1]
GO:0034260;negative regulation of GTPase activity;6.0;1.0;0.8231203125901445;9.628524252492122;61.14468506277762;5.970411137910149;0.0020464575824072424;0.6284474158353811;[TMED2, IQGAP2]
GO:0015760;glucose-6-phosphate transport;7.0;1.0;0.8509193652572005;9.628524252492122;35.11430155034197;7.9853141584524145;0.0011752440720702493;0.7592887026755414;[SLC37A1, G6PC3]
GO:0045454;cell redox homeostasis;5.0;1.0;0.7902410118609202;9.628524252492122;31.944097044200298;5.572381008289503;0.0010691401802485107;0.5752128357670632;[TXNRD1, PRDX1]
GO:0000387;spliceosomal snRNP assembly;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;66.59596265062147;6.166155715036245;0.002228906937441061;0.6662568552797195;[SNRPG]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[UBE2I, RNF38, SYVN1, FBXL15, ANAPC11, PSMD8, KBTBD4, KCTD10, PSMB1, FBXL3, ANAPC5, RFFL, C18orf25]
GO:0000271;polysaccharide biosynthetic process;5.0;0.6007507099811141;0.5906163668514773;8.155218514382602;120.41830338107809;6.039404009397101;0.004030292244727581;0.5990964137624962;[GLT8D1]
GO:2000582;positive regulation of ATP-dependent microtubule motor activity, plus-end-directed;7.0;1.0;0.8509193652572005;9.628524252492122;134.42213444296092;8.16763571524637;0.004498987867739075;0.7686126355688037;[DYNLL2]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[SGPL1]
GO:1901844;regulation of cell communication by electrical coupling involved in cardiac conduction;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;47.34252427509125;7.57984905034425;0.0015845116819816402;0.7626338329336335;[CALM1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[TLE4, DR1, UBE2I, HDAC3, HDAC1, YY1, NIPBL, CNOT1, NFIC, SAP130, TPR, SP3, MTF2, EP300, LCOR, TAF7, LRRFIP1, ZNF564, ZNF189]
GO:0048863;stem cell differentiation;4.0;0.7043150770688792;0.6021575385344395;8.242229891372231;21.066225782797595;5.734022359845919;7.050676185779127E-4;0.5432381701418294;[MTF2]
GO:2000210;positive regulation of anoikis;8.0;1.0;0.875;9.628524252492122;103.81651994310933;7.8311634786251565;0.0034746454936938316;0.7754860644832351;[PTRH2]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTP4A1, DUSP23, PTPRA, DUSP28]
GO:0033151;V(D)J recombination;10.0;0.8436909121759173;0.837086467948879;9.4949928598676;161.93311326735065;7.138016298065211;0.0054197555707179;0.7802794972956796;[DCLRE1C]
GO:0032060;bleb assembly;6.0;1.0;0.8231203125901445;9.628524252492122;58.56724312331254;7.474488534686424;0.001960192920240494;0.7053660038532718;[EMP3]
GO:0046329;negative regulation of JNK cascade;12.0;0.9326813400603323;0.9144609826203107;9.607904965289386;1764.4523437695266;6.280566066213989;0.05905463204195212;0.7693087532925187;[HDAC3, PAFAH1B1]
GO:0000245;spliceosomal complex assembly;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;66.59596265062147;6.444869117505266;0.002228906937441061;0.6805102716434839;[SNRPG, USP39]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[BECN1, HDAC3, CSNK2A1, SPHK2, HDAC1, DOCK8, SYVN1, CIB1, AATF, SETX, CFDP1, PTRH2, NUP62, CASP2, VDAC2, RFFL]
GO:0006904;vesicle docking involved in exocytosis;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;32.65265176272962;6.039404009397101;0.0010928548690198408;0.6319757144917204;[VPS18, VPS33B, RABEPK]
GO:0034599;cellular response to oxidative stress;4.0;0.7248374789738407;0.6124187394869203;8.935377071932177;68.67201153720991;4.519578255652688;0.0022983904253524798;0.48113144217596127;[SETX, BECN1, TXNRD1, PRDX1]
GO:0009060;aerobic respiration;6.0;0.7671156992804218;0.7066781622303554;8.874752450115741;31.550561209678754;5.926926025970411;0.0010559688900263317;0.6262235851885184;[CHCHD5, NDUFS7, COX4I1, COX5B]
GO:0070898;RNA polymerase III transcriptional preinitiation complex assembly;8.0;1.0;0.875;9.628524252492122;67.28910983117808;8.390779266560578;0.002252105949782328;0.8041048419030481;[TBP]
GO:0015853;adenine transport;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;31.75392616320175;8.16763571524637;0.0010627753320041709;0.7686126355688037;[VDAC3]
